Editor’s Note: Since the PACIFIC study established sequential immunotherapy following chemoradiotherapy as the standard of care for unresectable stage III non-small cell lung cancer (NSCLC), the global focus has shifted…

Editor’s Note: A deep understanding of the dynamic changes within the tumor microenvironment is crucial to accurately assess treatment response and disease progression in cancer patients. At the 2025 ASCO…

Nasopharyngeal carcinoma (NPC) is a malignancy with high prevalence in Southern China and other Southeast Asian countries, imposing a significant disease burden. Treatment options for recurrent/metastatic NPC (R/M NPC) remain limited. In recent years, immune checkpoint inhibitors (ICIs) have brought new hope to this patient population, and domestically developed ICIs in China have demonstrated promising efficacy.

In celebration of the 2025 National Science and Technology Workers Day and International Children’s Day, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College hosted a public science outreach event as part of the National Open Day at the National Key Laboratory of Hematology and Health. Over 200 primary and secondary school students from Tianjin, accompanied by their parents, participated in the event. The Deputy Director of Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Dr. Xiaoli Liu, delivered opening remarks, and the event was chaired by Mr. Chuan Wang, Director of the Education Office.

Editor’s Note: The 2025 ASCO Annual Meeting is currently in full swing across the Pacific, and several China-led clinical studies in breast cancer have captured significant international attention. Among them,…

Editor’s Note: Small cell lung cancer (SCLC), often referred to as the “king of lung cancers,” has seen little change in its first-line treatment over the past 30 years, with…

Editor's Note: At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, the ANCHOR study, led by Professor Kefeng Ding from The Second Affiliated Hospital Zhejiang University School of…

&t=47s

The 2025 ASCO Annual Meeting successfully concluded in Chicago on June 3( local time). Hengrui Pharma delivered a strong international presence, featuring 15 innovative drugs and 72 research outcomes. These included 4 oral presentations, 5 rapid oral presentations, 27 poster presentations, and 36 online publications. Multiple groundbreaking research advances has elicited widespread discussion among global experts.